Hepatology · Article 191

How Should Patients Be Followed After Hepatitis C Cure?

Hepatitis C cure follow-up requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Hepatitis C cure follow-up clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Hepatitis C cure follow-up: practical clinical approach

This page focuses on Hepatitis C cure follow-up with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Hepatitis C cure follow-up

Clinical takeaway: For Hepatitis C cure follow-up, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: After sustained virologic response (SVR), patients without cirrhosis generally do not require ongoing HCV-specific liver follow-up unless they have another liver disease or ongoing risk for reinfection. Patients with cirrhosis remain at risk for HCC and portal-hypertension complications and require continued surveillance. People with ongoing exposure risk should receive harm-reduction counseling and HCV RNA testing at least annually or whenever liver enzymes rise.

Cure is durable but not immunity

HCV antibodies remain positive and do not protect against reinfection.

Cirrhosis does not disappear overnight

Fibrosis may regress after cure, but HCC risk remains sufficient for continued surveillance.

Persistent ALT after SVR deserves a new diagnosis

Consider MASLD, alcohol, HBV, autoimmune disease or another cause.

Practical clinical algorithm

1. Confirm SVR with HCV RNA ≥12 weeks after therapy.

2. If no cirrhosis and no other liver disease, return to routine care.

3. If cirrhosis, continue HCC surveillance and portal-hypertension management.

4. If reinfection risk persists, test HCV RNA annually.

5. Investigate persistent abnormal liver tests for another cause.

Common mistakes to avoid

Repeating HCV antibody to look for cure.
Stopping HCC surveillance in cirrhosis.
Assuming abnormal ALT means HCV relapse.
Ignoring reinfection risk.
Continuing unnecessary specialty visits in a cured noncirrhotic patient with no other liver disease.

Trainee takeaway

After HCV cure, follow the liver disease that remains—not the virus that is gone.

Frequently asked questions

Does HCV antibody become negative?

Usually no.

Do noncirrhotic patients need HCC surveillance?

Generally no.

How do you test for reinfection?

HCV RNA, not antibody.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Practice Review in Hepatopancreaticobiliary Diseases and Nutrition. CAPstone Academic Publishers; 2014.

3. AASLD-IDSA HCV Guidance. Follow-Up After Achieving Virologic Cure (SVR).

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions